Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study

MLA

Cecilia Arthur, et al. “Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study.” Frontiers in Oncology, vol. 12, July 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.899325.

APA

Cecilia Arthur, Fatemah Rezayee, Nina Mogensen, Leonie Saft, Richard Rosenquist, Magnus Nordenskjöld, Arja Harila-Saari, Emma Tham, & Gisela Barbany. (2022). Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.899325

Chicago

Cecilia Arthur, Fatemah Rezayee, Nina Mogensen, Leonie Saft, Richard Rosenquist, Magnus Nordenskjöld, Arja Harila-Saari, Emma Tham, and Gisela Barbany. 2022. “Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study.” Frontiers in Oncology 12 (July). doi:10.3389/fonc.2022.899325.